AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-PREPACKAGED SOFTWARE
CAMBRIDGE ANTIBODY TECH GR ADS
Q · usd
SIC 7372 · SERVICES-PREPACKAGED SOFTWARE
FIGI AK-DCA81F573A
7.22▼ 9.24 (-56.14%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
16.46
Day's Range
16.28 – 16.60
52-Week Range
12.48 – 16.60
Volume
54.3K
Avg Volume
24.9K
Share Statistics
Shares Outstanding
Employees
—
Exchange
Q
Listed
—
Share count as of April 30, 2026

CAMBRIDGE ANTIBODY TECH GR ADS (CATG) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about CAMBRIDGE ANTIBODY TECH GR ADS (CATG)
What is CAMBRIDGE ANTIBODY TECH GR ADS's Market Cap?
CAMBRIDGE ANTIBODY TECH GR ADS's Market Cap is $15.4M, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's Enterprise Value?
CAMBRIDGE ANTIBODY TECH GR ADS's Enterprise Value is $28.1M, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's Price / Sales?
CAMBRIDGE ANTIBODY TECH GR ADS's Price / Sales is 5.8×, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's EV / Revenue?
CAMBRIDGE ANTIBODY TECH GR ADS's EV / Revenue is 10.7×, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's EV / EBITDA?
CAMBRIDGE ANTIBODY TECH GR ADS's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's Revenue (TTM)?
CAMBRIDGE ANTIBODY TECH GR ADS's Revenue (TTM) is $2.6M, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's Net Income (TTM)?
CAMBRIDGE ANTIBODY TECH GR ADS's Net Income (TTM) is -$8.9M, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's EBITDA?
CAMBRIDGE ANTIBODY TECH GR ADS's EBITDA is -$6.5M, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's Diluted EPS (TTM)?
CAMBRIDGE ANTIBODY TECH GR ADS's Diluted EPS (TTM) is -4.19, based on as-reported figures from SEC (XBRL) filings.
What is CAMBRIDGE ANTIBODY TECH GR ADS's EBITDA Margin?
CAMBRIDGE ANTIBODY TECH GR ADS's EBITDA Margin is -246.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CATGAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemAug 31, 2025Aug 31, 2024
Data revenue
Media activation revenue
Total revenue
YoY growth-12.1%
Data cost of sales
Media activation cost of sales
Total cost of sales
Gross profit (loss)
% of revenue54.2%
Expenses
Non-Operating Income (Expense)
Other Expense
Selling, General and Administrative Expense
Depreciation Expense
Provision for Doubtful Accounts (CF)
Total Costs and Expenses
Impairment Charges (CF)—
Loss on disposition of software assets—
Total operating expenses
% of revenue331.8%
Other income (expense)
Interest expense
Total Interest Income—
Gain on exchange of convertible notes payable for Series B convertible preferred stock
Loss recognized upon dissolution of DrivenIQ
Net loss before allowance for income taxes
Net loss
% of revenue-309.3%
Net loss attributable to the non-controlling interest
Net loss attributable to VisitIQ Corp.
% of revenue-302.2%
Preferred stock cumulative dividends
Net loss attributable to common stockholders
Earnings Per Share (Basic)
Earnings Per Share (Diluted)